Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor

Background CLR457 is an orally bioavailable pan-phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) inhibitor. Methods CLR457 anti-tumor activity and pharmacokinetics (PK) were characterized by in vitro biochemical assays and in vivo tumor xenografts. A first-in-human study was conducted to determ...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Invest New Drugs
Main Authors: Harding, James J., Bauer, Todd M., Tan, Daniel S. W., Bedard, Philippe L., Rodon, Jordi, Doi, Toshihiko, Schnell, Christian, Iyer, Varsha, Baffert, Fabienne, Radhakrishnan, Rajkumar, Fabre, Claire, Juric, Dejan
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2018
Assuntos:
Phase I Studies
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6440935/
https://ncbi.nlm.nih.gov/pubmed/30073466
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-018-0627-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados